Academic Journal
Q2High Blood Pressure and Cardiovascular Prevention
About High Blood Pressure and Cardiovascular Prevention
High Blood Pressure and Cardiovascular Prevention is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q2, with an SJR of 0.824 and H-index of 40.
Coverage: 2004-2026. Research categories: Cardiology and Cardiovascular Medicine (Q2); Internal Medicine (Q2).
Verified field sources
- Journal Impact Factor: 2.9 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Editor(s): Massimo Volpe MD, FAHA, FESC (Editor-in-Chief) — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Source-backed journal facts
Topics in published research
Blood Pressure and Hypertension Studies; Hormonal Regulation and Hypertension; Cardiovascular Health and Disease Prevention; Heart Rate Variability and Autonomic Control; Sodium Intake and Health; Cardiovascular Function and Risk Factors.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
2,890.00 USD; 4,290.00 EUR
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
The Impact of Antihypertensive De-escalation: A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT)
Fanxing Du, Steven M. Smith, Janie Coulombe, Mark S. Segal et al.
2026-09-19 · DOI: 10.1007/s40292-026-00822-4Pilot Randomised Controlled Trial Comparing Two Digital Solutions in the Management of Hypertensive Patients
Luigi De Luca, Alessandro Croce, Davide Soranna, Antonella Zambon et al.
2026-09-19 · DOI: 10.1007/s40292-026-00823-3Interventional Treatment of Arterial Hypertension in The Modern Era: An Updated Review from the Young Investigator Group of the European Society of Hypertension
Yusuf Ziya Şener, Costantino Mancusi, Alexandr Ceasovschih, Andrej Belančić et al.
2026-09-06 · DOI: 10.1007/s40292-026-00821-5Lean Mass Reduction During Glucagon-like Peptide-1 Receptor Agonists-Induced Weight Loss: Rethinking Its Clinical Significance
Federica Moscucci, Giuliano Tocci, Giulia Nardoianni, Carmine Savoia et al.
2026-09-06 · DOI: 10.1007/s40292-026-00819-zAssociation of Dietary Inflammatory Index and Dietary Oxidative Balance Score with Mortality Among Individuals with Cardiovascular–Kidney–Metabolic Syndrome
Xiaohua Wang, Hewanmeng Geng, Zihang Yue, Jiaqi Zhang et al.
2026-08-18 · DOI: 10.1007/s40292-026-00820-6Pathophysiology and Clinical Relevance of Microvascular Remodeling in Arterial Hypertension
Matteo Lemoli, Claudia Agabiti Rosei, Giacomo Buso, Claudia Rossini et al.
2026-07-31 · DOI: 10.1007/s40292-026-00813-5Efficacy and Safety of SGLT-2 Inhibitors in Patients with Uncontrolled or Resistant Hypertension: A Pilot Meta-Analysis of Randomized Clinical Trials
Omer Mohammed, Sun Hyeok Kim, Aditya Karthikeyan, Nehal Eid et al.
2026-07-31 · DOI: 10.1007/s40292-026-00817-1Efficacy and Safety of the Extemporaneous Combination Nebivolol/Amlodipine in Patients with Hypertension Uncontrolled on Monotherapy: The BOTTICELLI Study
Massimo Volpe, Giovambattista Desideri, Ralf Dechend, Philippe Van De Borne et al.
2026-07-31 · DOI: 10.1007/s40292-026-00816-2Orthostatic Hypotension in Hypertensive Patients Hospitalized in Italian Internal Medicine Departments: FADOI-HYP-OP Study
Claudio Ferri, Alberto Mazza, Dario Manfellotto, Francesco Dentali et al.
2026-07-15 · DOI: 10.1007/s40292-026-00808-2Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis
Adir Alper, Adina Fagin, Aditya Karthikeyan, Avrohom Karp et al.
2026-07-15 · DOI: 10.1007/s40292-026-00814-4Pregnancy as a Window for Hypertension and Cardiovascular Prevention in Women: A Life-Course Perspective Based on the 2025 ESC Guidelines
Anna Vittoria Mattioli, Giulia Renda, Claudio Ferri, Sabina Gallina et al.
2026-07-15 · DOI: 10.1007/s40292-026-00815-3Hypertension Education, Provider, and Cardio-Cerebrovascular Symptom Awareness: 2024 Korea Community Health Survey
Nayoung Kang, Youngjae Kim, Sangah Park, Youngjin Ryu et al.
2026-07-11 · DOI: 10.1007/s40292-026-00811-7Cost-Effectiveness and Budget Impact Analysis of Radiofrequency Renal Denervation for Uncontrolled and Resistant Hypertension in Italy
Flavio L. Ribichini, Anne M. Ryschon, Elisa Tacconi, Simon A. Weber et al.
2026-06-30 · DOI: 10.1007/s40292-026-00810-8Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Luis E. Simental-Mendía, Laura Jazel Barragán-Zúñiga, Valeria Reyes-Avitia
2026-06-29 · DOI: 10.1007/s40292-026-00812-6Reciprocal Relationship Between Cardiovascular Risk and Attainment of Blood Pressure and Cholesterol Targets in Users of a Mobile Health App
Fabian Starnecker, Johannes Krefting, Leon Nissen, Marius Schwab et al.
2026-06-04 · DOI: 10.1007/s40292-026-00806-4Atherogenic Index of Plasma as Predictor for Cardiovascular Events and Cardiometabolic Diseases:Findings from the PAMELA Study
Alessandro Maloberti, Rita Facchetti, Ana Jelakovic, Cesare Cuspidi et al.
2026-06-02 · DOI: 10.1007/s40292-026-00807-3Phenotype-Guided Renal Denervation: the Key to Therapeutic Response
Ehsan Shahverdi, Lars Roman Herda, Sendooran Shahi, Mathias Lange et al.
2026-06-02 · DOI: 10.1007/s40292-026-00809-1Impaired Intracranial Compliance: A New Hypertension-Mediated Brain Organ Damage?
Mikaelle C. Correia, Sayuri Inuzuka, Matheus Martins da Costa, Ana Luiza Lima Sousa et al.
2026-05-29 · DOI: 10.1007/s40292-026-00804-6Natriuretic Peptides as a Biomarker of Cognitive Decline in Hypertension
Giovanna Gallo, Gianmarco Dutti, Maurizio Volterrani, Massimo Fini et al.
2026-05-19 · DOI: 10.1007/s40292-026-00805-5Correction: Triglyceride-Glucose Index and Mortality Risk in the General Population: A Systematic Review and Meta-analysis of Prospective Studies
Lanfranco D’Elia, Saverio Stranges, Ersilia La Fata, Francesca Fortunato et al.
2026-05-19 · DOI: 10.1007/s40292-026-00802-8Reviews
Community Reviews
Version History
October 2, 2026 at 8:47 pm
October 2, 2026